Lifetech Sci (01302) is currently up more than 4%. As of the time of writing, the stock has risen 4.43% to HK$1.65, with a turnover of HK$43.5211 million. On the news front, Lifetech Sci announced that on January 7, 2026, its self-developed G-iliacPro Iliac Artery Stent Graft System received formal registration approval from the National Medical Products Administration (NMPA) of China. The product is indicated for the endovascular treatment of abdominal aortic aneurysm combined with iliac artery aneurysm or isolated common iliac artery aneurysm. By reconstructing the internal iliac artery to ensure pelvic blood supply, it provides a more mature and comprehensive solution for clinical practice, representing a systematic upgrade to existing treatment options.